A detailed history of Rhumbline Advisers transactions in Vaccitech PLC stock. As of the latest transaction made, Rhumbline Advisers holds 60 shares of VACC stock, worth $204. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60
Previous 60 -0.0%
Holding current value
$204
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023

BUY
$1.68 - $3.16 $100 - $189
60 New
60 $0

Others Institutions Holding VACC

About Vaccitech plc


  • Ticker VACC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,216,200
  • Market Cap $127M
  • Description
  • Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B...
More about VACC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.